SK Life Science, Inc., the U.S. subsidiary of SK Biopharmaceuticals, is an innovative global pharmaceutical company focused on the research, development and treatment of central nervous system (CNS) disorders. The company has a pipeline of eight compounds in development for CNS disorders including epilepsy. Learn more about SK Life Science, Inc.
At Eisai, we give our first thoughts to patients and their families and helping to increase the benefits health care provides. We call it human health care (hhc). We are committed to providing innovative approaches that help those patients with the greatest unmet medical needs and contributing to the health and well-being of people worldwide. Learn more.
UCB’s goal is to command a leading position in discovering and developing new therapies to treat patients suffering from severe diseases. With a promising pipeline, our focus is on neurological and immunological diseases to provide new treatments for specialists and their patients. Learn more.
We are LivaNova, and we’re leading the way in cardiovascular and neuromodulation solutions. By putting patients first, we’re committed to developing breakthrough treatments and innovations that improve patients’ quality of life every day. This commitment to patients and those who care for them drives everything we do. Learn more.
The Danny Did Foundation works toward its mission to prevent deaths caused by seizures with these main goals in mind: advancing public awareness of Sudden Unexpected Death in Epilepsy (SUDEP), enhancing SUDEP education and disclosure between medical professionals and families afflicted by seizures, and the mainstreaming of seizure detection and prediction devices that may assist in preventing seizure-related deaths. Learn more.
Contact Nicole Murray – firstname.lastname@example.org
We are proud of our sponsors and appreciate their continued support